CordenPharma is investing €80 million over multiple years to expand sterile injectable manufacturing at its FDA- and EMA-approved Caponago site near Milan, Italy. The program includes the €13 million acquisition of an adjacent 11,000-square-meter commercial building and 26,000 square meters of land, completed on 28 July 2026, increasing the site footprint by more than 50%. The expanded facility can accommodate at least four aseptic fill-and-finish lines, four visual inspection lines and four packaging lines, alongside customer-owned lines, large-scale lyophilization and auto-injector assembly. Existing-site upgrades add two isolator lines, expanded automatic secondary packaging and doubled analytical capacity. The new lines are targeted for completion in mid-2027 and 2028, with combined milestones projected to raise capacity to up to 500 million injectable units annually across peptides, LNPs, small molecules, biologics and oligonucleotides.